Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБНУ «Научный центр психического здоровья», Москва, Россия *ikolykhalov@yandex.ru
Список исп. литературыСкрыть список 1. Solomon PR, Murphy CA. Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice. Geriatrics 2005; 60 (11): 26–31. 2. Behl C, Ziegler C. Beyond amyloid – widening the view on Alzheimer’s disease. J Neurochem 2017; 143: 394–5. DOI: 10.1111/jnc.14137 3. Weinstein JD. A new direction for Alzheimer's research. Neural Regen Res 2018; 13 (2): 190–3. DOI: 10.4103/1673-5374.226381 4. Aliev G, Palacios HH, Gasimov E et al. Oxidative stress induced mitochondrial failure and vascular hypoperfusion as a key initiator for the development of Alzheimer disease. Pharmaceuticals (Basel) 2010; 3 (1): 158–87. DOI: 10.3390/ph3010158 5. Calderon-Garcidueñas AL, Duyckaerts C. Alzheimer disease. Handb Clin Neurol 2017; 145: 325–37. DOI: 10.1016/B978-0-12-802395-2.00023-7 6. Twohig D, Rodriguez-Vieitez E, Sando SB et al. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease. Acta Neuropathol Commun 2018; 6: 130. DOI: 10.1186/s40478-018-0624-z 7. Vergallo A, Bun RS, Toschi N et al.; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Association of cerebrospinal fluid α-synuclein with total and phospho-tau. Alzheimers Dement 2018; 14: 1623–31. DOI: 10.1016/j.jalz.2018.06.3053 8. González-Reyes RE, Nava-Mesa MO, Vargas-Sánchez K et al. Involvement of astrocytes in Alzheimer’s disease from a neuroinflammatory and oxidative stress perspective. Front Mol Neurosci 2017; 10: 427. DOI: 10.3389/fnmol.2017.00427 9. Yucesoy B, Peila R, White LR et al. Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: the Honolulu-Asia aging Study. Neurobiol Aging 2006; 27: 211–7. DOI: 10.1016/j.neurobiolaging.2005.01.013 10. Zilka N, Ferencik M, Hulin I. Neuroinflammation in Alzheimer’s disease: protector or promoter? Bratisl Lek Listy 2006; 107: 374–83. 11. Iadecola C. Rescuing troubled vessels in Alzheimer disease. Nat Med 2005; 11: 923–4. DOI: 10.1038/nm0905-923 12. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 2011; 12: 723–38. DOI: 10.1038/nrn3114 13. Govindpani K, McNamara LG, Smith NR et al. Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It? J Clin Med 2019; 8: 651. DOI: 10.3390/jcm8050651 14. Bennett DA. Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery. PLoS Med 2017; 14 (3): 1–4 e1002256. DOI: 10.1371/journal.pmed.1002256 15. Alvarez-Guerra M, Bertholom N, Garay RP. Selective blockade by nicergoline of vascular responses elicited by stimulation of alphaiA-adrenoceptor subtype in the rat. Fundam Clin Pharmacol 1999; 13 (1): 50–8. 16. Carfagna N, Di Clemente A, Cavanus S et al. Modulation of hippocampal ACh release by chronic nicergoline treatment in freely moving young and aged rats. Neurosci Lett 1995; 197: 195–8. 17. Winblad B, Fioravanti M, Dolezal T et al. Therapeutic use of nicergoline. Clin Drug Investig 2008; 28 (9): 533–52. 18. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001; 4: CD003159. 19. Im JJ, Jeong HS, Park JS et al. Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study. Dement Neurocogn Disord 2017; 16 (4): 104–9. DOI: 10.12779/dnd.2017.16.4.104 20. Winblad B, Bonura ML, Rossini BM, Battaglia A. Nicergoline in the treatment of mild-to-moderate Alzheimer’s disease: a European multicentre trial. Clin Drug Invest 2001; 21 (9): 621–32. 21. Hao M, Ren X, Guo S et al. A Meta-analysis on nicergoline in the treatment of cognitive impairment. J of Shanxi Medical University 2017; 5: 479–84. 22. Пономарева Е.В. Применение ницерголина (Cермиона) в комплексной терапии деменций позднего возраста в амбулаторной практике. Психиатрия. 2017; 73 (1): 49–59. / Ponomareva E.V. Primenenie nitsergolina (Cermiona) v kompleksnoi terapii dementsii pozdnego vozrasta v ambulatornoi praktike. Psikhiatriia. 2017; 73 (1): 49–59. [in Russian] 23. Nappi G, Bono G, Merlo P et al. Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia: Results of a Multicentre, Double-Blind, Placebo-Controlled Study. Clin Drug Investig 1997; 13 (6): 308–16. DOI: 10.2165/00044011-199713060-00003 24. Fioravanti M, Nakashima T, Xu J, Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open 2014; 4 (7): e005090. DOI: 10.1136/bmjopen-2014-005090 25. Bachurin SO, Gavrilova SI, Samsonova A et al. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res 2018; 129: 216–26. DOI: 10.1016/j.phrs.2017.11.021 26. Jongsiriyanyong S, Limpawattana P. Mild Cognitive Impairment in Clinical Practice: A Review Article. Am J Alzheimers Dis Other Demen 2018; 33 (8): 500–7. DOI: 10.1177/1533317518791401